Datavault AI (NASDAQ:DVLT) surged in early trading Tuesday after the data-monetization specialist sharply raised its fiscal 2025 revenue outlook, citing an "exceptional" acceleration in enterprise AI adoption and licensing fees.
Daily Journal (NASDAQ:DJCO) posted first-quarter fiscal 2026 revenue of $19.5 million, up 10% from $17.7 million in the year-ago period.
Enlight Renewable Energy (NASDAQ:ENLT) delivered a record-shattering fourth-quarter performance on Tuesday, as the global energy developer capitalized on a surge in U.S. solar and storage demand to handily exceed its full-year guidance.
National Energy Services Reunited (NASDAQ:NESR) delivered a powerhouse performance for the fourth quarter on Tuesday, as a sharp acceleration in Middle Eastern field activity propelled the company toward a record-breaking 2026.
Medtronic (NYSE:MDT) reported third-quarter fiscal 2026 revenue of $9.017 billion, an increase of 8.7% as reported and 6.0% on an organic basis, surpassing the midpoint of its guidance by 50 basis points and marking the highest enterprise revenue growth in the past 10 quarters.
Fluor (NYSE:FLR) reported a volatile set of full-year 2025 results on Tuesday, as the engineering and construction giant navigated a major legal setback and a dramatic restructuring of its balance sheet.
Valmont Industries (NYSE:VMI) reported fourth-quarter fiscal 2025 net sales of $1.04 billion, essentially flat year over year with a 0.1% increase, as growth in key infrastructure segments was offset by softer demand in certain agricultural markets.
Vulcan Materials Company (NYSE: VMC) reported full-year 2025 adjusted EBITDA of $2.324 billion, an increase of 13% from the prior year, marking a record high for the company.
Danaher (NYSE:DHR) announced it has signed a definitive agreement to acquire all outstanding shares of Masimo Corporation for $180 per share in cash, valuing the deal at approximately $9.9 billion on an enterprise basis.
Harmony Biosciences Holdings (NASDAQ:HRMY) announced Tuesday that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for WAKIX® (pitolisant) to treat cataplexy in pediatric patients aged six years and older.
Pfizer (NYSE:PFE) today reported positive topline results from Cohort 3 of its pivotal Phase 3 BREAKWATER trial, marking a significant milestone in the treatment of one of the most aggressive forms of colorectal cancer.
SunCoke Energy (NYSE:SXC) reported a full-year 2025 net loss attributable to SXC of $44.2 million, or $0.52 per diluted share, compared with prior-year performance, primarily due to unfavorable one-time items totaling $109.3 million pre-tax ($83.1 million net of tax).
